# EDGAR Filing Document

**Accession Number:** 0000107140
**File Stem:** 0000107140-26-000009
**Filing Date:** 2026-3
**Character Count:** 80462
**Document Hash:** af89c648f28dfd6464f41863de300903
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000107140-26-000009.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0000107140-26-000009

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 43

**CONFORMED PERIOD OF REPORT**: 20260305

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JOHN WILEY & SONS, INC.
- **CENTRAL INDEX KEY:** 0000107140
- **STANDARD INDUSTRIAL CLASSIFICATION:** BOOKS: PUBLISHING OR PUBLISHING AND PRINTING [2731]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 135593032
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11507
- **FILM NUMBER:** 26724773

**BUSINESS ADDRESS:**
- **STREET 1:** 111 RIVER STREET
- **CITY:** HOBOKEN
- **STATE:** NJ
- **ZIP:** 07030
- **BUSINESS PHONE:** 2017486000

**MAIL ADDRESS:**
- **STREET 1:** 111 RIVER STREET
- **CITY:** HOBOKEN
- **STATE:** NJ
- **ZIP:** 07030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WILEY JOHN & SONS, INC.
- **DATE OF NAME CHANGE:** 20070820

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WILEY JOHN & SONS INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? jwa-20260305

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

March 5, 2026

(Date of Report)

(Date of earliest event reported)

**JOHN WILEY & SONS, INC.**

(Exact name of registrant as specified in its charter)

**New York**

(State or other jurisdiction of incorporation)

---

| | |
|:---|:---|
| **001-11507** | **13-5593032** |
| (Commission File Number) | (IRS Employer Identification No.) |
| **111 River Street, Hoboken New Jersey**  | **07030** |
| (Address of principal executive offices) | (Zip Code) |
| Registrant's telephone number, including area code: | **(201) 748-6000** |

---

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Class A Common Stock, par value $1.00 per share | WLY | New York Stock Exchange |
| Class B Common Stock, par value $1.00 per share | WLYB | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 2.02 Results of Operations and Financial Condition.**

On March 5, 2026, John Wiley & Sons Inc., a New York corporation (the "Company"), issued a press release announcing the Company's financial results for the third quarter of fiscal year 2026. A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 7.01 Regulation FD Disclosure.**

On March 5, 2026, the Company held its third quarter of fiscal year 2026 earnings conference call. The Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K the presentation materials that were provided and discussed during the earnings conference call.

The information included in Items 2.02 and 7.01, including the exhibits hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

**<u>Exhibit No. Description</u>**

<u>[99.1](ex991.htm)</u> - Press release dated March 5, 2026 "AI Momentum, Material Margin Expansion, and Cash Flow Growth Highlight Wiley's Third Quarter 2026"

<u>[99.2](exhibit992-q326earningsp.htm)</u> - Presentation materials dated March 5, 2026.

104 - Cover Page Interactive Data File (embedded within the Inline XBRL document).

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **JOHN WILEY & SONS, INC.** | **JOHN WILEY & SONS, INC.** | **JOHN WILEY & SONS, INC.** |
| (Registrant) | (Registrant) | (Registrant) |
| | By | /s/ Matthew S. Kissner |
| | | Matthew S. Kissner |
| | | President and Chief Executive Officer |
| | Dated: March 5, 2026 | Dated: March 5, 2026 |

---

## Exhibit 99.1

![image.jpg](image.jpg)

**AI Momentum, Material Margin Expansion, and Cash Flow Growth Highlight Wiley's Third Quarter 2026** 

*March 5, 2026 - Hoboken, NJ –* Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning, today reported results for the third quarter ended January 31, 2026.

**THIRD QUARTER SUMMARY**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **GAAP performance vs. prior year**: Revenue of $410 million up 1%; Operating Income of $63 million up 21%; and Diluted Earnings Per Share (EPS) of $0.56 compared to prior year loss of ($0.43)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted Results at constant currency**: Revenue of $410 million flat as expected due to unfavorable comparisons in Research and market-related softness in Learning; Adjusted Operating Income of $70 million up 22% and margin of 17% up 280 basis points; Adjusted EBITDA of $105 million up 12% and margin of 25.7% up 250 basis points; and Adjusted EPS of $0.97 up 19%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Research Publishing momentum:** Delivered 3% revenue growth as reported (+1% at constant currency as expected). Research Publishing grew 4% at constant currency excluding an unfavorable comparison to prior year related to an AI agreement, driven by growth in our recurring revenue and open access models

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **AI and data services momentum:** Realized $7 million of AI revenue this quarter and approximately $42 million year-to-date. Launched Clinical Outcomes Assessments partnership with IQVIA and announced a new AI and Data Services leader. After quarter close, Wiley executed a strategic partnership and recurring revenue agreement with OpenEvidence for AI clinical decision support

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Continued operational excellence:** Reduced Corporate Expenses (Adjusted EBITDA) by 21% at constant currency as part of multi-year margin expansion initiatives; announced technology managed services partnership to drive material operating efficiencies and cost savings

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Cash Flow growth (YTD):** Operating Cash Flow increased by $51 million to $103 million with Free Cash Flow of $56 million up from a use of ($1 million) in prior year. On track to realize $200 million of Free Cash Flow in Fiscal 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Significant increase in return to shareholders:** Increased share repurchases to $35 million this quarter with a full year target of $100 million; allocated $126 million to share repurchases and dividends year-to-date

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Fiscal 2026 outlook:** Guiding to high end of range for Adjusted EBITDA margin and Adjusted EPS; reaffirming Revenue and Free Cash Flow outlook

**MANAGEMENT COMMENTARY** 

"We continue to accelerate our progress in major areas of focus, from driving Research and AI growth to delivering materially higher margins and cash flow," said Matthew Kissner, President and CEO. "In Research Publishing, we're leveraging our scale and competitive moat to grow market share and drive record publishing output, with AI as a further accelerator. In AI and data services, we're leveraging our proprietary content and unparalleled partner ecosystem to execute strategic multi-year agreements with corporations in life sciences and other verticals. We recently surpassed $100 million in lifetime AI revenue and secured our first LLM customer outside the US. Finally, margin expansion remains our company-wide ethos as evidenced by our 280 basis point improvement in our Adjusted Operating Margin."

------

**FINANCIAL SUMMARY**

*Please see the accompanying financial tables for more detail.* 

**RESEARCH SEGMENT** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Q3 Research revenue of $274 million was up 2% as reported and 1% at constant currency driven by 1% growth in Research Publishing or 4% excluding unfavorable comparison to prior year related to AI revenue. Article submissions and output rose by 26% and 11% year-to-date, respectively, with robust demand to publish across both fast growing and mature markets. Strong volume drove growth in both author-funded open access and multi-year licenses for research institutions. Research Solutions was down 3% at constant currency largely due to softness in recruiting and databases offsetting higher licensing revenue. Year-to-date, Research revenue was up 5% as reported and 4% at constant currency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Q3 Adjusted EBITDA of $91 million was up 4% as reported and 3% at constant currency driven by revenue growth and cost savings initiatives. Adjusted EBITDA margin for the quarter was 33.1% vs. 32.7% in the prior year period. Year-to-date, Research Adjusted EBITDA was up 7% as reported or 6% at constant currency.

**LEARNING SEGMENT** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Q3 Learning revenue of $136 million was down 1% as reported or 2% at constant currency. Academic grew 2% or 1% at constant currency driven by licensing and digital content growth offsetting declines in print and digital courseware. Professional was down 5% at constant currency driven by soft retail channel and market conditions offsetting higher licensing revenue. Year-to-date, Learning revenue was down 7% as reported and at constant currency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Q3 Adjusted EBITDA of $48 million for the quarter was flat as reported and down 1% at constant currency. Adjusted EBITDA margin was up twenty basis points to 35.6% with favorable product mix and restructuring savings offsetting lower revenue. Year-to-date, Learning Adjusted EBITDA was down 8% as reported and at constant currency.

**CORPORATE EXPENSES** 

*"Corporate Expenses" are the portion of shared services costs not allocated to segments.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Q3 Corporate Expenses on an Adjusted EBITDA basis were lower by 20% as reported and 21% at constant currency due to restructuring savings and expense management across functional areas, namely Technology. Year-to-date, Corporate Expenses on an Adjusted EBITDA basis were lower by 12% as reported and constant currency.

**EPS** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Q3 GAAP EPS** of $0.56 compared to a loss of ($0.43) in the prior year period. **Q3 Adjusted EPS** of $0.97 was up 15% as reported or 19% at constant currency driven by operating performance and lower share count offset by a higher adjusted effective tax rate. Year-to-date, GAAP EPS was up $1.33 and Adjusted EPS 13% at constant currency.

**BALANCE SHEET, CASH FLOW, AND CAPITAL ALLOCATION** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Net Debt-to-EBITDA Ratio** (Trailing Twelve Months) at quarter end was 1.7 compared to 2.0 in the year-ago period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Net Cash Provided by Operating Activities** was $103 million year-to-date compared to $52 million in the prior year period driven by higher cash earnings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Free Cash Flow** improved to $56 million year-to-date from a use of $1 million in the prior year period. Free Cash Flow was driven by higher cash earnings and lower capex. Capex was $48 million compared to $53 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Returns to Shareholders:** During the quarter, Wiley allocated $54 million in the quarter toward repurchases ($35 million) and dividends ($19 million), up 86% over prior year. Year-to-date, Wiley allocated $126 million to repurchases ($70 million) and dividends ($56 million), an increase of 37% compared to the prior year period. Wiley repurchased approximately 1.09 million shares in Q3 and 1.98 million shares year-to-date.

------

**FISCAL 2026 OUTLOOK** 

Wiley is guiding to the high end of the range for Adjusted EBITDA margin and Adjusted EPS and reaffirming Adjusted Revenue and Free Cash Flow. Research and AI momentum are expected to remain strong.

---

| | | | |
|:---|:---|:---|:---|
| **Metric** | **Fiscal 2025 Results** | **Fiscal 2026 Outlook** | **Q3 2026 Update** |
| **Adj. Revenue** | $1,660M | Low-single digit growth | **Reaffirmed** |
| **Adj. EBITDA Margin** | 24% | 25.5% to 26.5% | **High end of range** |
| **Adj. EPS** | $3.64 | $3.90 to $4.35 | **High end of range** |
| **Free Cash Flow** | $126M | Approximately $200M | **Reaffirmed** |

---

*Adjusted metrics exclude year over year impact of divestitures, which were primarily completed in Fiscal 2024 with remainder completed in first half of Fiscal 2025*

**EARNINGS CALL**

Scheduled for today, March 5 at 10:00 am (ET). Access webcast at Investor Relations at investors.wiley.com, or directly at https://events.q4inc.com/attendee/463112721. U.S. callers, please dial (888) 210-3346 and enter the participant code 2521217#. International callers, please dial (646) 960-0253 and enter the participant code 2521217#**.** 

**ABOUT WILEY** 

Wiley (NYSE: WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.

**NON-GAAP FINANCIAL MEASURES**

Wiley provides non-GAAP financial measures and performance results such as "Adjusted EPS," "Adjusted Operating Income and Margin," "EBITDA, Adjusted EBITDA and Margin," "Adjusted Income before Taxes," "Adjusted Income Tax Provision," "Adjusted Effective Tax Rate," "Free Cash Flow less Product Development Spending," "Adjusted Revenue," and results on a Constant Currency basis to assess underlying business performance and trends. Management believes non-GAAP financial measures, which exclude the impact of restructuring charges and credits and certain other items, and the impact of divestitures and acquisitions provide a useful comparable basis to analyze operating results and earnings. See the reconciliations of non-GAAP financial measures and explanations of the uses of non-GAAP measures in the supplementary information. We have not provided our 2026 outlook for the most directly comparable U.S. GAAP financial measures, as they are not available without unreasonable effort due to the high variability, complexity, and low visibility with respect to certain items, including restructuring charges and credits, gains and losses on foreign currency, and other gains and losses. These items are uncertain, depend on various factors, and could be material to our consolidated results computed in accordance with U.S. GAAP.

------

**FORWARD-LOOKING STATEMENTS** 

This release contains certain forward-looking statements concerning the Company's operations, performance, and financial condition. Reliance should not be placed on forward-looking statements, as actual results may differ materially from those in any forward-looking statements. Any such forward-looking statements are based upon a number of assumptions and estimates that are inherently subject to uncertainties and contingencies, many of which are beyond the control of the Company and are subject to change based on many important factors. Such factors include, but are not limited to: (i) the level of investment in new technologies and products; (ii) subscriber renewal rates for the Company's journals; (iii) the financial stability and liquidity of journal subscription agents; (iv) the consolidation of book wholesalers and retail accounts; (v) the market position and financial stability of key online retailers; (vi) the seasonal nature of the Company's educational business and the impact of the used book market; (vii) worldwide economic and political conditions; (viii) the Company's ability to protect its copyrights and other intellectual property worldwide (ix) the ability of the Company to successfully integrate acquired operations and realize expected opportunities; (x) the ability to realize operating savings over time and in fiscal year 2026 in connection with our multiyear Global Restructuring Program and completed dispositions; (xi) cyber risk and the failure to maintain the integrity of our operational or security systems or infrastructure, or those of third parties with which we do business; (xii) as a result of acquisitions, we have and may record a significant amount of goodwill and other identifiable intangible assets and we may never realize the full carrying value of these assets; (xiii) our ability to leverage artificial intelligence technologies in our products and services, including generative artificial intelligence, large language models, machine learning, and other artificial intelligence tools; and (xiv) other factors detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events.

CATEGORY: EARNINGS RELEASES

**Contact** 

Brian Campbell

Investor Relations

brian.campbell@wiley.com

201.748.6874 <br>

------

**JOHN WILEY & SONS, INC.**

**SUPPLEMENTARY INFORMATION** <sup>(1) (2)</sup>

**CONDENSED CONSOLIDATED STATEMENTS OF NET INCOME (LOSS)**

**(in USD thousands, except per share information)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2026** | **2025** | **2026** | **2025** |
| **Revenue, net** | $**410036** | $**404626** | $**1228587** | $**1235030** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Costs and expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | 107781 | 104219 | 321428 | 320439 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating and administrative expenses | 219097 | 229960 | 684514 | 717670 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | 7057 | 5574 | 16127 | 13071 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 13343 | 13042 | 39801 | 38913 |
| **Total costs and expenses** | **347278** | **352795** | **1061870** | **1090093** |
| **Operating income** | **62758** | **51831** | **166717** | **144937** |
| *As a % of revenue* | *15.3 %* | *12.8 %* | *13.6 %* | *11.7 %* |
| Interest expense | (11490) | (14027) | (34202) | (41277) |
| Net foreign exchange transaction losses | (5187) | (4222) | (5202) | (7316) |
| Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | (161) | (15930) | (3586) | (9760) |
| Other (expense) income, net | (1524) | 1021 | (3614) | 4029 |
| **Income before taxes** | **44396** | **18673** | **120113** | **90613** |
| Provision for income taxes | 14717 | 41627 | 33843 | 74545 |
| *Effective tax rate* | *33.1 %* | *222.9 %* | *28.2 %* | *82.3 %* |
| **Net income (loss)** | $**29679** | $**(22954)** | $**86270** | $**16068** |
| *As a % of revenue* | *7.2 %* | *-5.7 %* | *7.0 %* | *1.3 %* |
| **Earnings (loss) per share** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.57 | $(0.43) | $1.63 | $0.30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted<sup>(3)</sup> | $0.56 | $(0.43) | $1.62 | $0.29 |
| **Weighted average number of common shares outstanding** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 52245 | 53952 | 52904 | 54173 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted<sup>(3)</sup> | 52657 | 53952 | 53371 | 54815 |

---

---

| |
|:---|
| **Notes:** |
| (1) The supplementary information included in this press release for the three and nine months ended January 31, 2026 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. |
| (2) All amounts are approximate due to rounding. |
| (3) In calculating diluted net loss per common share for the three months ended January 31, 2025, our diluted weighted average number of common shares outstanding excludes the effect of unvested restricted stock units and other stock awards as the effect was antidilutive. This occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive. |

---

------

**JOHN WILEY & SONS, INC.**

**SUPPLEMENTARY INFORMATION** <sup>(1) (2)</sup>

**RECONCILIATION OF US GAAP MEASURES to NON-GAAP MEASURES**

**(in USD thousands, except per share information)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of US GAAP Earnings (Loss) per Share to Non-GAAP Adjusted EPS** | **Reconciliation of US GAAP Earnings (Loss) per Share to Non-GAAP Adjusted EPS** | **Reconciliation of US GAAP Earnings (Loss) per Share to Non-GAAP Adjusted EPS** | **Reconciliation of US GAAP Earnings (Loss) per Share to Non-GAAP Adjusted EPS** | **Reconciliation of US GAAP Earnings (Loss) per Share to Non-GAAP Adjusted EPS** |
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
|  | **2026** | **2025** | **2026** | **2025** |
| **US GAAP Earnings (Loss) Per Share - Diluted** | $**0.56** | $**(0.43)** | $**1.62** | $**0.29** |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | 0.11 | 0.09 | 0.24 | 0.21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments | 0.04 | 0.09 | 0.03 | 0.09 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 0.21 | 0.20 | 0.64 | 0.62 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | 0.03 | 0.29 | 0.09 | 0.20 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Held for Sale or Sold segment Adjusted Net Loss |  |  |  | 0.05 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax adjustments | 0.02 | 0.58 | (0.06) | 0.82 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EPS impact of using weighted-average dilutive shares for adjusted EPS calculation<sup>(3)</sup> |  | 0.02 |  |  |
| **Non-GAAP Adjusted Earnings Per Share - Diluted** | $**0.97** | $**0.84** | $**2.56** | $**2.28** |
| **Reconciliation of US GAAP Income Before Taxes to Non-GAAP Adjusted Income Before Taxes** | **Reconciliation of US GAAP Income Before Taxes to Non-GAAP Adjusted Income Before Taxes** | **Reconciliation of US GAAP Income Before Taxes to Non-GAAP Adjusted Income Before Taxes** | **Reconciliation of US GAAP Income Before Taxes to Non-GAAP Adjusted Income Before Taxes** | **Reconciliation of US GAAP Income Before Taxes to Non-GAAP Adjusted Income Before Taxes** |
|  | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
|  | **2026** | **2025** | **2026** | **2025** |
| **US GAAP Income Before Taxes** | $**44396** | $**18673** | $**120113** | $**90613** |
| Pretax Impact of Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | 7057 | 5574 | 16127 | 13071 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments | 3430 | 5239 | 1880 | 5590 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 13343 | 13042 | 39801 | 38956 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | 161 | 15930 | 3586 | 9760 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Held for Sale or Sold segment Adjusted Loss Before Taxes |  |  |  | 3578 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement |  |  | 108 |  |
| **Non-GAAP Adjusted Income Before Taxes** | $**68387** | $**58458** | $**181615** | $**161568** |
| **Reconciliation of US GAAP Income Tax Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate** | **Reconciliation of US GAAP Income Tax Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate** | **Reconciliation of US GAAP Income Tax Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate** | **Reconciliation of US GAAP Income Tax Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate** | **Reconciliation of US GAAP Income Tax Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate** |
| **US GAAP Income Tax Provision** | $**14717** | $**41627** | $**33843** | $**74545** |
| Income Tax Impact of Adjustments<sup>(4)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | 1448 | 404 | 3238 | 1315 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments | 1314 | 260 | 346 | 599 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 1859 | 1910 | 5985 | 5511 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | (1257) | 154 | (1203) | (1360) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Held for Sale or Sold segment Adjusted Tax Benefit |  |  |  | 887 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement | **—** | **—** | **—** | **—** |
| Income Tax Adjustments |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impact of withholding tax on Sri Lanka distribution | (1208) |  | (1208) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impact of valuation allowance on the US GAAP effective tax rate | 305 | (31744) | 334 | (44863) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impact of change in Germany statutory tax rate on deferred tax balances |  |  | 3869 |  |
| **Non-GAAP Adjusted Income Tax Provision** | $**17178** | $**12611** | $**45204** | $**36634** |
| **US GAAP Effective Tax Rate** | **33.1%** | **222.9%** | **28.2%** | **82.3%** |
| **Non-GAAP Adjusted Effective Tax Rate** | **25.1%** | **21.6%** | **24.9%** | **22.7%** |

---

---

| |
|:---|
| **Notes:** |
| (1) All amounts are approximate due to rounding. |
| (2) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. |
| (3) Represents the impact of using diluted weighted-average number of common shares outstanding (54.6 million shares for the three months ended January 31, 2025) included in the Non-GAAP Adjusted EPS calculation in order to apply the dilutive impact on adjusted net income due to the effect of unvested restricted stock units and other stock awards. This impact occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive. |
| (4) For the three and nine months ended January 31, 2026 and 2025, respectively, substantially all of the tax impact was from deferred taxes. |

---

------

**JOHN WILEY & SONS, INC.**

**SUPPLEMENTARY INFORMATION** <sup>(1) (2)</sup>

**RECONCILIATION OF US GAAP NET INCOME (LOSS) TO NON-GAAP EBITDA AND ADJUSTED EBITDA**

**(in USD thousands)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2026** | **2025** | **2026** | **2025** |
| **Net Income (Loss)** | $**29679** | $**(22954)** | $**86270** | $**16068** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 11490 | 14027 | 34202 | 41277 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 14717 | 41627 | 33843 | 74545 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 35592 | 36474 | 107967 | 110445 |
| **Non-GAAP EBITDA** | **91478** | **69174** | **262282** | **242335** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related charges | 7057 | 5574 | 16127 | 13071 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net foreign exchange transaction losses | 5187 | 4222 | 5202 | 7316 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | 161 | 15930 | 3586 | 9760 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expense (income), net | 1524 | (1021) | 3614 | (4029) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Held for Sale or Sold segment Adjusted EBITDA |  |  |  | 3578 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement |  |  | 108 |  |
| **Non-GAAP Adjusted EBITDA** | $**105407** | $**93879** | $**290919** | $**272031** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA Margin* | *25.7 %* | *23.2 %* | *23.7 %* | *22.3 %* |

---

---

| |
|:---|
| **Notes:** |
| (1) All amounts are approximate due to rounding. |
| (2) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. |

---

------

**JOHN WILEY & SONS, INC.**

**SUPPLEMENTARY INFORMATION** <sup>(1) (2) (3)</sup>

**SEGMENT RESULTS**

**(in USD thousands)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | | **% Change** | **% Change** |
| | **Three Months Ended<br>January 31,** | **Three Months Ended<br>January 31,** | **Favorable (Unfavorable)** | **Favorable (Unfavorable)** |
| | **2026** | **2025** | **Reported** | **Constant Currency** |
| **Research:** |  |  |  |  |
| **Revenue, net** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research Publishing | $233435 | $225874 | 3% | 1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research Solutions | 40684 | 41670 | -2% | -3% |
| **Total Revenue, net** | $**274119** | $**267544** | **2%** | **1%** |
| **Non-GAAP Adjusted Operating Income** | $**67731** | $**65669** | **3%** | **3%** |
| Depreciation and amortization | 23024 | 21918 | -5% | -3% |
| **Non-GAAP Adjusted EBITDA** | $**90755** | $**87587** | **4%** | **3%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA margin* | *33.1 %* | *32.7 %* |  |  |
| **Learning:** |  |  |  |  |
| **Revenue, net** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Academic | $80108 | $78795 | 2% | 1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Professional | 55809 | 58287 | -4% | -5% |
| **Total Revenue, net** | $**135917** | $**137082** | **-1%** | **-2%** |
| **Non-GAAP Adjusted Operating Income** | $**38270** | $**37764** | **1%** | **1%** |
| Depreciation and amortization | 10179 | 10761 | 5% | 6% |
| **Non-GAAP Adjusted EBITDA** | $**48449** | $**48525** | **0%** | **-1%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA margin* | *35.6 %* | *35.4 %* |  |  |
| **Held for Sale or Sold:** |  |  |  |  |
| **Total Revenue, net** | $**—** | $**—** | **#** | **#** |
| **Non-GAAP Adjusted Operating Loss** | $**—** | $**—** | **#** | **#** |
| Depreciation and amortization |  |  | # | # |
| **Non-GAAP Adjusted EBITDA** | $**—** | $**—** | **#** | **#** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA margin* | *0.0 %* | *0.0 %* |  |  |
| **Corporate Expenses:** |  |  |  |  |
| **Non-GAAP Adjusted Corporate Expenses** | $**(36186)** | $**(46028)** | **21%** | **22%** |
| Depreciation and amortization | 2389 | 3795 | 37% | 37% |
| **Non-GAAP Adjusted EBITDA** | $**(33797)** | $**(42233)** | **20%** | **21%** |
| **Consolidated Results:** |  |  |  |  |
| **Revenue, net** | $**410036** | $**404626** | **1%** | **0%** |
| Less: Held for Sale or Sold Segment |  |  | # | # |
| **Adjusted Revenue, net** | $**410036** | $**404626** | **1%** | **0%** |
| **Operating Income** | $**62758** | $**51831** | **21%** | **21%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges | 7057 | 5574 | -27% | -27% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Held for Sale or Sold Segment Adjusted Operating Loss |  |  | # | # |
| **Non-GAAP Adjusted Operating Income** | $**69815** | $**57405** | **22%** | **22%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted Operating Income margin* | *17.0 %* | *14.2 %* |  |  |
| Depreciation and amortization | 35592 | 36474 | 2% | 4% |
| Less: Held for Sale or Sold Segment depreciation and amortization |  |  | # | # |
| **Non-GAAP Adjusted EBITDA** | $**105407** | $**93879** | **12%** | **12%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA margin* | *25.7 %* | *23.2 %* |  |  |

---

---

| |
|:---|
| **Notes:** |
| (1) The supplementary information included in this press release for the three and nine months ended January 31, 2026 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. |
| (2) All amounts are approximate due to rounding. |
| (3) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. |
| # Variance greater than 100% |

---

------

**JOHN WILEY & SONS, INC.**

**SUPPLEMENTARY INFORMATION** <sup>(1) (2) (3)</sup>

**SEGMENT RESULTS**

**(in USD thousands)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | | **% Change** | **% Change** |
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** | **Favorable (Unfavorable)** | **Favorable (Unfavorable)** |
| | **2026** | **2025** | **Reported** | **Constant Currency** |
| **Research:** |  |  |  |  |
| **Revenue, net** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research Publishing | $706644 | $679492 | 4% | 2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research Solutions | 127681 | 115246 | 11% | 10% |
| **Total Revenue, net** | $**834325** | $**794738** | **5%** | **4%** |
| **Non-GAAP Adjusted Operating Income** | $**193940** | $**180412** | **7%** | **7%** |
| Depreciation and amortization | 69728 | 66999 | -4% | -2% |
| **Non-GAAP Adjusted EBITDA** | $**263668** | $**247411** | **7%** | **6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA margin* | *31.6 %* | *31.1 %* |  |  |
| **Learning:** |  |  |  |  |
| **Revenue, net** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Academic | $222610 | $233547 | -5% | -5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Professional | 171652 | 189363 | -9% | -10% |
| **Total Revenue, net** | $**394262** | $**422910** | **-7%** | **-7%** |
| **Non-GAAP Adjusted Operating Income** | $**106680** | $**116135** | **-8%** | **-8%** |
| Depreciation and amortization | 30703 | 32952 | 7% | 7% |
| **Non-GAAP Adjusted EBITDA** | $**137383** | $**149087** | **-8%** | **-8%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA margin* | *34.8 %* | *35.3 %* |  |  |
| **Held for Sale or Sold:** |  |  |  |  |
| **Total Revenue, net** | $**—** | $**17382** | **#** | **#** |
| **Non-GAAP Adjusted Operating Loss** | $**—** | $**(3578)** | **#** | **#** |
| Depreciation and amortization |  |  | # | # |
| **Non-GAAP Adjusted EBITDA** | $**—** | $**(3578)** | **#** | **#** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA margin* | *0.0 %* | *-20.6 %* |  |  |
| **Corporate Expenses:** |  |  |  |  |
| **Non-GAAP Adjusted Corporate Expenses** | $**(117668)** | $**(134961)** | **13%** | **13%** |
| Depreciation and amortization | 7536 | 10494 | 28% | 28% |
| **Non-GAAP Adjusted EBITDA** | $**(110132)** | $**(124467)** | **12%** | **12%** |
| **Consolidated Results:** |  |  |  |  |
| **Revenue, net** | $**1228587** | $**1235030** | **-1%** | **-2%** |
| Less: Held for Sale or Sold Segment |  | (17382) | # | # |
| **Adjusted Revenue, net** | $**1228587** | $**1217648** | **1%** | **0%** |
| **Operating Income** | $**166717** | $**144937** | **15%** | **15%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges | 16127 | 13071 | -23% | -23% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Held for Sale or Sold Segment Adjusted Operating Loss |  | 3578 | # | # |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal settlement | 108 | **—** | # | # |
| **Non-GAAP Adjusted Operating Income** | $**182952** | $**161586** | **13%** | **13%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted Operating Income margin* | *14.9 %* | *13.3 %* |  |  |
| Depreciation and amortization | 107967 | 110445 | 2% | 4% |
| Less: Held for Sale or Sold depreciation and amortization |  |  | # | # |
| **Non-GAAP Adjusted EBITDA** | $**290919** | $**272031** | **7%** | **6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Adjusted EBITDA margin* | *23.7 %* | *22.3 %* |  |  |

---

# Variance greater than 100%

------

**JOHN WILEY & SONS, INC.**

**SUPPLEMENTARY INFORMATION** <sup>(1) (2)</sup>

**CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**

**(in USD thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **January 31,<br>2026** | **April 30,<br>2025** |
| **Assets:** | | |
| **Current assets** | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $95115 | $85882 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 200220 | 228410 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 19295 | 22875 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 96621 | 102717 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | **411251** | **439884** |
| Technology, property and equipment, net | 141708 | 162125 |
| Intangible assets, net | 595100 | 595044 |
| Goodwill | 1138748 | 1121505 |
| Operating lease right-of-use assets | 60442 | 66128 |
| Other non-current assets | 214079 | 306780 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $**2561328** | $**2691466** |
| **Liabilities and shareholders' equity:** |  |  |
| **Current liabilities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $50099 | $60948 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued royalties | 177204 | 109765 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term portion of long-term debt | 11250 | 10000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities | 292840 | 462693 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued employment costs | 69830 | 93117 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term portion of operating lease liabilities | 16242 | 18282 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | 74950 | 66051 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | **692415** | **820856** |
| Long-term debt | 796288 | 789435 |
| Accrued pension liability | 72960 | 71899 |
| Deferred income tax liabilities | 106589 | 105145 |
| Operating lease liabilities | 73614 | 81482 |
| Other long-term liabilities | 69487 | 70443 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | **1811353** | **1939260** |
| **Shareholders' equity** | **749975** | **752206** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and shareholders' equity** | $**2561328** | $**2691466** |

---

---

| |
|:---|
| **Notes:** |
| (1) The supplementary information included in this press release for January 31, 2026 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. |
| (2) All amounts are approximate due to rounding. |

---

------

**JOHN WILEY & SONS, INC.**

**SUPPLEMENTARY INFORMATION** <sup>(1) (2)</sup>

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in USD thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
| | **2026** | **2025** |
| **Operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income | $86270 | $16068 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale | 3586 | 9760 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 39801 | 38913 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of product development assets | 11707 | 12669 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization of technology, property, and equipment | 56459 | 58863 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other noncash charges | 73955 | 68095 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net change in operating assets and liabilities | (168466) | (152118) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | **103312** | **52250** |
| **Investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions to technology, property, and equipment | (37984) | (42347) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product development spending | (9785) | (11054) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Businesses acquired in purchase transactions, net of cash acquired |  | (915) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash proceeds (transferred) related to the sale of businesses and assets | 114126 | (11239) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisitions of publication rights and other | (20751) | (4139) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used in) investing activities** | **45606** | **(69694)** |
| **Financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net debt borrowings | 1087 | 114319 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash dividends | (56303) | (57243) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of treasury shares | (69963) | (35421) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (14793) | 2421 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash (used in) provided by financing activities** | **(139972)** | **24076** |
| **Effects of exchange rate changes on cash, cash equivalents and restricted cash** | **287** | **(1615)** |
| **Change in cash, cash equivalents and restricted cash for period** | **9233** | **5017** |
| **Cash, cash equivalents and restricted cash - beginning** | **85932** | **99543** |
| **Cash, cash equivalents and restricted cash - ending** | $**95165** | $**104560** |
| **CALCULATION OF NON-GAAP FREE CASH FLOW LESS PRODUCT DEVELOPMENT SPENDING** <sup>(3)</sup> | **CALCULATION OF NON-GAAP FREE CASH FLOW LESS PRODUCT DEVELOPMENT SPENDING** <sup>(3)</sup> | **CALCULATION OF NON-GAAP FREE CASH FLOW LESS PRODUCT DEVELOPMENT SPENDING** <sup>(3)</sup> |
|  | **Nine Months Ended<br>January 31,** | **Nine Months Ended<br>January 31,** |
|  | **2026** | **2025** |
| **Net cash provided by operating activities** | $**103312** | $**52250** |
| Less: Additions to technology, property, and equipment | (37984) | (42347) |
| Less: Product development spending | (9785) | (11054) |
| **Free cash flow less product development spending** | $**55543** | $**(1151)** |

---

---

| |
|:---|
| **Notes:** |
| (1) The supplementary information included in this press release for the nine months ended January 31, 2026 is preliminary and subject to change prior to the filing of our upcoming Quarterly Report on Form 10-Q with the Securities and Exchange Commission. |
| (2) All amounts are approximate due to rounding. |
| (3) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. |

---

------

**JOHN WILEY & SONS, INC.**

**EXPLANATION OF USAGE OF NON-GAAP PERFORMANCE MEASURES**

In this earnings release and supplemental information, management may present the following non-GAAP performance measures:

• Adjusted Earnings Per Share (Adjusted EPS);

• Free Cash Flow less Product Development Spending;

• Adjusted Revenue;

• Adjusted Operating Income and margin;

• Adjusted Income Before Taxes;

• Adjusted Income Tax Provision;

• Adjusted Effective Tax Rate;

• EBITDA, Adjusted EBITDA and margin; and

• Results on a constant currency basis.

Management uses these non-GAAP performance measures as supplemental indicators of our operating performance and financial position as well as for internal reporting and forecasting purposes, when publicly providing our outlook, to evaluate our performance and calculate incentive compensation.

We present these non-GAAP performance measures in addition to US GAAP financial results because we believe that these non-GAAP performance measures provide useful information to certain investors and financial analysts for operational trends and comparisons over time. The use of these non-GAAP performance measures may also provide a consistent basis to evaluate operating profitability and performance trends by excluding items that we do not consider to be controllable activities for this purpose.

The performance metric used by our chief operating decision maker to evaluate performance of our reportable segments is Adjusted Operating Income. We present both Adjusted Operating Income and Adjusted EBITDA for each of our reportable segments as we believe Adjusted EBITDA provides additional useful information to certain investors and financial analysts for operational trends and comparisons over time. It removes the impact of depreciation and amortization expense, as well as presents a consistent basis to evaluate operating profitability and compare our financial performance to that of our peer companies and competitors.

For example:

• Adjusted EPS, Adjusted Revenue, Adjusted Operating Income and margin, Adjusted Income Before Taxes, Adjusted Income Tax Provision, Adjusted Effective Tax Rate, EBITDA, and Adjusted EBITDA and margin provide a more comparable basis to analyze operating results and earnings and are measures commonly used by shareholders to measure our performance.

• Free Cash Flow less Product Development Spending helps assess our ability, over the long term, to create value for our shareholders as it represents cash available to repay debt, pay common stock dividends, and fund share repurchases and acquisitions.

• Results on a constant currency basis remove distortion from the effects of foreign currency movements to provide better comparability of our business trends from period to period. We measure our performance excluding the impact of foreign currency (or at constant currency), which means that we apply the same foreign currency exchange rates for the current and equivalent prior period.

In addition, we have historically provided these or similar non-GAAP performance measures and understand that some investors and financial analysts find this information helpful in analyzing our operating margins and net income, and in comparing our financial performance to that of our peer companies and competitors. Based on interactions with investors, we also believe that our non-GAAP performance measures are regarded as useful to our investors as supplemental to our US GAAP financial results, and that there is no confusion regarding the adjustments or our operating performance to our investors due to the comprehensive nature of our disclosures.

We have not provided our 2026 outlook for the most directly comparable US GAAP financial measures, as they are not available without unreasonable effort due to the high variability, complexity, and low visibility with respect to certain items, including restructuring charges and credits, gains and losses on foreign currency, and other gains and losses. These items are uncertain, depend on various factors, and could be material to our consolidated results computed in accordance with US GAAP.

Non-GAAP performance measures do not have standardized meanings prescribed by US GAAP and therefore may not be comparable to the calculation of similar measures used by other companies and should not be viewed as alternatives to measures of financial results under US GAAP. The adjusted metrics have limitations as analytical tools, and should not be considered in isolation from, or as a substitute for, US GAAP information. It does not purport to represent any similarly titled US GAAP information and is not an indicator of our performance under US GAAP. Non-GAAP financial metrics that we present may not be comparable with similarly titled measures used by others. Investors are cautioned against placing undue reliance on these non-GAAP measures.

## Exhibit 99.2

![](exhibit992-q326earningsp001.jpg)

Third Quarter 2026 Earnings Review NYSE: WLY MARCH 05, 2026

------

![](exhibit992-q326earningsp002.jpg)

SAFE HARBOR STATEMENT This release contains certain forward-looking statements concerning the Company's operations, performance, and financial condition. Reliance should not be placed on forward-looking statements, as actual results may differ materially from those in any forward-looking statements. Any such forward- looking statements are based upon a number of assumptions and estimates that are inherently subject to uncertainties and contingencies, many of which are beyond the control of the Company and are subject to change based on many important factors. Such factors include, but are not limited to: (i) the level of investment in new technologies and products; (ii) subscriber renewal rates for the Company's journals; (iii) the financial stability and liquidity of journal subscription agents; (iv) the consolidation of book wholesalers and retail accounts; (v) the market position and financial stability of key online retailers; (vi) the seasonal nature of the Company's educational business and the impact of the used book market; (vii) worldwide economic and political conditions; (viii) the Company's ability to protect its copyrights and other intellectual property worldwide (ix) the ability of the Company to successfully integrate acquired operations and realize expected opportunities; (x) the ability to realize operating savings over time and in fiscal year 2026 in connection with our multiyear Global Restructuring Program and completed dispositions; (xi) cyber risk and the failure to maintain the integrity of our operational or security systems or infrastructure, or those of third parties with which we do business; (xii) as a result of acquisitions, we have and may record a significant amount of goodwill and other identifiable intangible assets and we may never realize the full carrying value of these assets; (xiii) our ability to leverage artificial intelligence technologies in our products and services, including generative artificial intelligence, large language models, machine learning, and other artificial intelligence tools; and (xiv) other factors detailed from time to time in our filings with the SEC. The Company undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances. NON-GAAP FINANCIAL MEASURES Wiley provides non-GAAP financial measures and performance results such as:  Adjusted Revenue  Adjusted Earnings Per Share ("Adjusted EPS");  Free Cash Flow;  Adjusted Operating Income and margin;  Adjusted Income Before Taxes  Adjusted Income Tax Provision  Adjusted Effective Tax Rate  EBITDA (earnings before interest, taxes, depreciation and amortization), Adjusted EBITDA and margin; and  Results on a constant currency ("CC") basis. Management believes non-GAAP financial measures, which exclude the impact of restructuring charges and credits and certain other items, and the impact of divestitures and acquisitions provide a useful comparable basis to analyze operating results and earnings. See the reconciliations of non-GAAP financial measures and explanations of the uses of non-GAAP measures in the supplementary information. We have not provided our 2026 outlook for the most directly comparable U.S. GAAP financial measures, as they are not available without unreasonable effort due to the high variability, complexity, and low visibility with respect to certain items, including restructuring charges and credits, gains and losses on foreign currency, and other gains and losses. These items are uncertain, depend on various factors, and could be material to our consolidated results computed in accordance with U.S. GAAP. 2

------

![](exhibit992-q326earningsp003.jpg)

Authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning

------

![](exhibit992-q326earningsp004.jpg)

Third Quarter Summary Driving continued strength in Research Publishing with record submissions and output, double-digit open access growth, and strong progress in our multi-year renewals; Learning performance as expected Accelerating progress in AI and Data Services with new leadership, strategic multi-year partnerships with life sciences companies, and $42 million of AI revenue realized year-to-date Advancing technology transformation with the announcement of a multi-year technology managed services partnership; Corporate Expenses reduced by 21% vs. prior year period Delivering material margin expansion and cash flow growth with Adjusted Operating Margin and Adjusted EBITDA Margin up 280bps and 250bps; respectively; Operating Cash Flow nearly doubled to $103M Returning record cash to shareholders with YTD share repurchases doubling to $70M on a full year target of $100M; combined total of $126M returned in dividend and repurchases in nine months 1 2 4 3 5 Accelerated progress in all major areas of focus

------

![](exhibit992-q326earningsp005.jpg)

Delivering on our Fiscal 2026 Commitments OBJECTIVE STATUS YTD PROGRESS Lead in Research  Revenue growth: Research +4% at constant currency  Leading indicators: Submissions (+26%) and Output (+11%)  Global acceleration: Submissions in Brazil (+77%), India (+43%), China (+24%), UK (+18%), Japan (+19%), US (+12%)  Research Platform milestones: 1,500+ journals or 80%+ of portfolio now migrated Journal portfolio: Expansion of world-leading Advanced brand with 8 new journals planned by end of 2026 for total of 30+; acquisition of leading Physics journal Deliver growth and value through AI and in adjacent markets  AI Revenue: $7M licensing agreements signed in Q3 with new AI model customers, including the first outside the US; $42M of total AI revenue realized YTD  Corporate R&D expansion: Announced strategic, recurring revenue partnership with OpenEvidence for clinical decision support and launched clinical outcome assessments partnership with IQVIA; in discussions with others; strong momentum with subscription agreements or pilots with 10 corporate customers in targeted verticals  AI innovation: New leadership announced; Publisher partnerships now at 36 for Nexus content licensing service; 9,000 trial users on Gateway Drive operational excellence and discipline across the organization  Corporate costs: Reduced corporate expenses on Adjusted EBITDA basis by 21% in quarter and 12% year-to-date. Reduced total corporate costs before allocations by $17 million year-to-date  Tech transformation: Accelerating with multi-year tech managed services partnership  Disciplined investments: Paying off with journal expansion and AI licensing

------

![](exhibit992-q326earningsp006.jpg)

Wiley's Value Drivers Accelerating Research core growth and share gains from strong moat, global scale, and favorable demand trends Driving new AI and data services growth from proprietary content advantage in critical AI domains and unparalleled partner ecosystem Continuing multi-year margin expansion with tech transformation, shared services optimization, and AI productivity Disciplined portfolio and capital allocation with high-return reinvestments and returns to shareholders; continuing to drive ROIC higher

------

![](exhibit992-q326earningsp007.jpg)

Research Growth: Funding and Multi-Year Renewals • Proposed US Administration cuts to scientific funding largely rejected by Congress with continuing strong bi-partisan support and federal investment in scientific discovery underpinning national competitiveness and economic growth • Global R&D funding and scientific investment historically strong and getting stronger; article output up every year since 1944 except one\*; R&D up 4-5% with the number of researchers growing 3% and AI productivity accelerating • Share of research output well dispersed across APAC (45%), Europe (31%), North America (18%), and ROW (6%) • CY26 journal renewal season stronger than anticipated as multi-year agreements remain must have for researchers and institutions worldwide • The wide moat publishers have a distinct advantage due to breadth and depth of content and proprietary data • Agreements viewed as mission critical to institutions with read and publish capabilities, author training, analytics and reporting – further strengthening retention • Further differentiators have been our AI-powered research capabilities through platforms like Research Exchange and Gateway 82% CY26 renewals closed; schedule in line with prior years 99% Expected customer retention, consistent over time Access to research remains core to institutions despite macro and political environments \*1971

------

![](exhibit992-q326earningsp008.jpg)

Research Growth: Global Demand & Open Access Output increasing from global expansion of research, driving double-digit open access growth Wiley Submissions Wiley Output Wiley Open Access Growth +26% +11% +24% YTD v. prior year Our Leading Open Access Journal and Advanced Portfolio • Advanced Science has rapidly become one of the world's leading journals in open access with a high impact rating and revenue growth of 50%; strong long-term outlook based on brand, quality, and the breadth of audience • Wiley's Advanced portfolio of journals is expected to exceed $70M in FY26 revenue, growing at strong double digits

------

![](exhibit992-q326earningsp009.jpg)

Wiley's Strategic Advantages in an AI Economy Must have, continually updating PROPRIETARY CONTENT Provides much of world's trusted scientific, technical, medical, and scholarly content and data through our portfolio and partner portfolios. Leading position in high-demand KNOWLEDGE DOMAINS Big 3 publisher and differentiated by top position in corporate R&D growth areas, including chemistry, materials, food science, engineering, etc. World renowned TRUST AND REPUTATION Wide moat journal portfolio and peer review networks; home to Nobel prize winning authors and the world's most prestigious societies Unencumbered market builder w/ FIRST MOVER ADVANTAGE Moving with speed and innovation with corporations and AI platform providers building out high-stakes AI models and applications Strategic connector with unrivalled PARTNER ECOSYSTEM Leveraging unmatched network of large AI partners, disruptors, corporations, institutions, other publishers, and societies Partnering w/ AI platform providers as CAPITAL LIGHT MODEL Ability to leverage existing assets, partnership ecosystem, and open platforms for high returns with minimal investment

------

![](exhibit992-q326earningsp010.jpg)

AI and Data Strategy Research & Learning Publishing (Foundational content and data, continually updating) AI-Powered Literature Search (AI Gateway for researchers and institutions) Domain-Specific Intelligence (Enriched data and AI solutions for corporations and partners) Life Sciences, Health, Engineering/Materials/Chem, Food & Ag, Finance Broad Academic Domains

------

![](exhibit992-q326earningsp011.jpg)

New AI and Data Leader Armughan Rafat • Leads Wiley's AI and data services strategy, driving innovation at the intersection of analytics, machine learning, and data solutions • Brings over 25 years leading complex technology and data organizations across life sciences, financial services, and publishing • Senior data analytics and technology roles at Norstella, Clarivate, ASI, and Thomson Reuters, where he developed products that generated hundreds of millions in annualized revenue • Published innovator with patents in machine learning; consistently converted content assets into high-margin data services and co-led integration for multi-billion-dollar acquisitions

------

![](exhibit992-q326earningsp012.jpg)

FY24 FY25 FY26P AI and Data Growth by the Numbers AI Revenue (increasing share from recurring) $40M $45M-$50M $23M • 10 Corporate Subscription Customers • 4 LLM Training Customers • 36 Nexus Publisher Partners for Scale • 9,000 Researcher Trial Users on Gateway • $100M+ Lifetime AI Revenue Overall $42M Q3

------

![](exhibit992-q326earningsp013.jpg)

AI and Data Growth: Clinical Outcome Assessments Clinical Outcome Assessments (COA) are scientifically validated instruments used in pharmaceutical trials to measure how patients feel, function, and respond to treatment. They are essential for demonstrating treatment impact and meeting regulatory standards for drug approval. Our collaboration with IQVIA transforms how we deliver this data, moving from copyright licensing to comprehensive, trial-ready solutions. Recently launched and strong early momentum. Wiley offers a comprehensive COA solution covering the full clinical trial implementation from licensing and multi-language translations to electronic migration, scientific support, and regulatory guidance. One Wiley-IQVIA partnership announced in Nov 2025 delivers what previously required multiple vendors. Transforming our large collection of Clinical Outcome Assessments into Pharmaceutical Solutions, shifting Wiley from rights provider to fast-growing clinical trial partner Wiley brings to partnership:  Our own validated COAs and manage on behalf of society partners, a portfolio of 100+ COA instruments across range of therapeutic areas  Established licensing infrastructure  Trusted scientific heritage IQVIA brings to partnership:  World's largest Contract Research Organization ($16B annual revenue)  Deep pharmaceutical relationships  Regulatory expertise and implementation capability Wiley COA Incremental Growth $800K in 2021 > $7M in 2026 and Rapidly Scaling

------

![](exhibit992-q326earningsp014.jpg)

AI and Data Growth: Clinical Point of Care Positioning Wiley as a strategic player in the clinical AI ecosystem through content licensing, equity investment, and future collaboration • OpenEvidence has rapidly emerged as the most widely used clinical decision support platform among U.S. physicians, with more than 40% of doctors using the platform daily across 10,000+ hospitals • Wiley and OpenEvidence have executed a 5-year agreement to integrate trusted content from Wiley journals and leading partners into the industry-leading clinical AI platform • Wiley will take a small equity position in OpenEvidence, positioning us as an ongoing strategic partner capturing growing opportunities in clinical decision support and corporate R&D • Includes Cochrane Database of Systematic Reviews—the gold standard for evidence-based clinical guidelines— and over 400 Wiley journals and books spanning critical specialties • Demonstrates how Wiley is enabling trusted access to scientific knowledge across multiple AI platforms and applications through responsible licensing frameworks; OpenEvidence expected to be a blueprint for others

------

![](exhibit992-q326earningsp015.jpg)

Performance Financial Position Outlook

------

![](exhibit992-q326earningsp016.jpg)

Third Quarter Results Revenue\* 0% $410M GAAP Diluted EPS ▲$0.99 $0.56 Adj. EPS\* ▲19% $0.97 Adj. EBITDA\* ▲12% $105M \*All variances are at constant currency. Revenue including favorable foreign exchange was up $5 million or +1%  Revenue performance as expected driven by Research growth of 1% offset by Learning decline of 2% from market headwinds in Professional; year-over-year performance impacted by AI revenue agreement in prior year  Adjusted EBITDA growth driven by material progress in reducing corporate expenses and driving Research margin expansion  Adjusted EBITDA margin up 250bps to 25.7%  Adjusted EPS growth driven by Adjusted Operating Income growth of 22%. Adjusted Operating Margin up 280bps to 17% Strong earnings growth and margin expansion highlight quarter; on track to deliver on guidance

------

![](exhibit992-q326earningsp017.jpg)

Research Performance  Research Publishing growth +4% excluding prior year AI revenue driven by strong demand and growth in recurring-revenue and open access models  Demand indicators, output trends, and outlook favorable; CY26 renewals tracking better than expected worldwide  Research Solutions performance impacted by revenue declines in recruitment and databases in a soft corporate marketing environment  Adjusted EBITDA growth up on revenue growth and cost savings; margin up 40bps Q3 Summary (millions) Q3 2026 Change Change CC Research Publishing $233 3% 1% Research Solutions $41 (2%) (3%) Total Revenue $274 2% 1% Adjusted EBITDA $91 4% 3% Adjusted EBITDA Margin 33.1% YTD 2026 Change Change CC $707 4% 2% $127 11% 10% $834 5% 4% $264 7% 6% 31.6%

------

![](exhibit992-q326earningsp018.jpg)

Learning Performance  Academic growth driven by digital content and licensing offsetting continued print declines  Professional revenue performance impacted by market-related challenges around consumer and corporate spending and Amazon channel inventories  Responding by reorganizing our editorial focus toward higher-value authors and titles, and accelerating our shift to digital products and inclusive access; targeted actions to protect margins  Adjusted EBITDA performance due to revenue performance; margin up 20bps to 35.6% (millions) Q3 2026 Change Change CC Academic $80 2% 1% Professional $56 (4%) (5%) Total Revenue $136 (1%) (2%) Adjusted EBITDA $48 0% (1%) Adjusted EBITDA Margin 35.6% YTD 2026 Change Change CC $223 (5%) (5%) $171 (9%) (10%) $394 (7%) (7%) $137 (8%) (8%) 34.8% Q3 Summary

------

![](exhibit992-q326earningsp019.jpg)

Strong Balance Sheet and Cash Flow $56M ($1M) Free Cash FlowCapex 1.7 2.0 TTM Jan 2025 TTM Jan 2026 Operating Cash Flow YTD25 YTD26 $52M $103M YTD25 YTD26 Leverage Ratio (Net Debt to EBITDA) YTD25 YTD26 $53M $48M Wiley on track for $200M FCF outlook

------

![](exhibit992-q326earningsp020.jpg)

Multi-Year Margin Expansion: Tech Transformation Creating a more cost effective, AI and data-enabled technology organization  Refocusing enterprise modernization on growth areas with AI-first approach  Consolidating locations and rationalizing application footprint; reducing tech debt  Freeing up capital for high return investments and the development of AI-powered customer solutions that leverage our content and domain advantages  Driving run-rate cash savings in FY27 and beyond — 5-year multi-year managed services partnership for enterprise IT services — Providing AI-first capabilities, scale, and efficiencies at a much faster pace — Partnership will improve delivery and free up internal teams to focus on product innovation — Driving material operational efficiencies and cost savings; freeing up capital to invest in high return AI solutions YTD Total Corporate Savings $17M (85% from tech transformation)

------

![](exhibit992-q326earningsp021.jpg)

Portfolio and Disciplined Capital Allocation Balancing high-return growth investments with returning cash to shareholders Organic investment Expanding our journal portfolio and proprietary content base, notably our Advanced portfolio; geographic expansion in fast growing Research markets; migrating remaining journals onto our best-in-class Research Exchange Platform; expanding AI capabilities and business development Portfolio optimization Evaluating portfolio for potential divestitures that no longer fit our growth or margin profile; divested a small business earlier this year M&A focus Targeting accretive journal acquisitions to add to our scale and content advantage; acquired a leading physics journal this year Return to shareholders Implementing record share buyback of $100M in FY26 due to cash flow outlook and undervaluation; $70 million repurchased year to date. $126M allocated to dividends and repurchases in nine months, up 37% over prior year

------

![](exhibit992-q326earningsp022.jpg)

Fiscal 2026 Outlook Metric Fiscal 2024 Fiscal 2025 Fiscal 2026 Outlook Dec 2025 Q3 Update March 2026 Adjusted Revenue $1,617M $1,660M Low-single digit growth Reaffirmed Adjusted EBITDA Margin 22.8% 24.0% 25.5% to 26.5% High end of range Adjusted EPS $2.78 $3.64 $3.90 to $4.35 High end of range Free Cash Flow $114M $126M Approximately $200M Reaffirmed Now projecting high end of range for Adjusted EBITDA margin and Adjusted EPS

------

![](exhibit992-q326earningsp023.jpg)

Looking Ahead to Fiscal 2027 Research growth and strong momentum driven by researcher productivity and strong publishing output, steady growth in renewals, market share gains, and society wins; Learning improving AI momentum accelerating from executed multi-year partnerships and increased corporate momentum; new leadership and organization streamlined; copyright court decisions expected Operational excellence initiatives fast-tracking with full launch of Research Exchange Platform, managed services partnership, and AI Center of Excellence Meaningful margin expansion continuing from tech transformation, corporate expense reduction, and AI productivity gains Relentless focus on portfolio optimization and disciplined capital allocation to drive higher ROIC and recurring-revenue growth while rewarding long term shareholders

------

![](exhibit992-q326earningsp024.jpg)

Executive Summary Accelerating progress in all major areas of focus — Driving strong growth and momentum in Research and AI — Materially expanding margins and cash flow — Deploying capital strategically and continuously improving ROIC Q3 in line with expectations; on track to achieve guidance Extremely well positioned in AI economy — Research has a wide moat that is robust and uniquely secure — Our proprietary content, domain-specific intelligence, and partnership ecosystems are significant advantages and in high demand — AI is only as good as the data that fuels it

------

![](exhibit992-q326earningsp025.jpg)

Thank you for joining us For more information or follow-up: investors.wiley.com brian.campbell@wiley.com

------

![](exhibit992-q326earningsp026.jpg)

Appendix - US GAAP to Non-GAAP Reconciliation Reconciliation of US GAAP Earnings (Loss) per Share to Non-GAAP Adjusted EPS 2026 2025 2026 2025 US GAAP Earnings (Loss) Per Share - Diluted 0.56$(0.43)$1.62$0.29$ Adjustments: Restructuring and related charges 0.11 0.09 0.24 0.21 Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments 0.04 0.09 0.03 0.09 Amortization of acquired intangible assets 0.21 0.20 0.64 0.62 Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale 0.03 0.29 0.09 0.20 Held for Sale or Sold segment Adjusted Net Loss - - - 0.05 Legal settlement - - - - Income tax adjustments 0.02 0.58 (0.06) 0.82 EPS impact of using weighted-average dilutive shares for adjusted EPS calculation (3) - 0.02 - - Non-GAAP Adjusted Earnings Per Share - Diluted 0.97$0.84$2.56$2.28$2026 2025 2026 2025 US GAAP Income Before Taxes 44,396$18,673$120,113$90,613$ Restructuring and related charges 7,057 5,574 16,127 13,071 Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments 3,430 5,239 1,880 5,590 Amortization of acquired intangible assets 13,343 13,042 39,801 38,956 Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale 161 15,930 3,586 9,760 Held for Sale or Sold segment Adjusted Loss Before Taxes - - - 3,578 Legal settlement - - 108 - Non-GAAP Adjusted Income Before Taxes 68,387$58,458$181,615$161,568$ US GAAP Income Tax Provision 14,717$41,627$33,843$74,545$ Restructuring and related charges 1,448 404 3,238 1,315 Foreign exchange losses on intercompany transactions, including the write off of certain cumulative translation adjustments 1,314 260 346 599 Amortization of acquired intangible assets 1,859 1,910 5,985 5,511 Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale (1,257) 154 (1,203) (1,360) Held for Sale or Sold segment Adjusted Tax Benefit - - - 887 Legal settlement - - - - Impact of withholding tax on Sri Lanka distribution (1,208) - (1,208) - Impact of valuation allowance on the US GAAP effective tax rate 305 (31,744) 334 (44,863) Impact of change in Germany statutory tax rate on deferred tax balances - - 3,869 - Non-GAAP Adjusted Income Tax Provision 17,178$12,611$45,204$36,634$ US GAAP Effective Tax Rate 33.1% 222.9% 28.2% 82.3% Non-GAAP Adjusted Effective Tax Rate 25.1% 21.6% 24.9% 22.7% Notes: (3) Represents the impact of using diluted weighted-average number of common shares outstanding (54.6 million shares for the three months ended January 31, 2025) included in the Non-GAAP Adjusted EPS calculation in order to apply the dilutive impact on adjusted net income due to the effect of unvested restricted stock units and other stock awards. This impact occurs when a US GAAP net loss is reported and the effect of using dilutive shares is antidilutive. (4) For the three and nine months ended January 31, 2026 and 2025, respectively, substantially all of the tax impact was from deferred taxes. Pretax Impact of Adjustments: Reconciliation of US GAAP Income Tax Provision to Non-GAAP Adjusted Income Tax Provision, including our US GAAP Effective Tax Rate and our Non-GAAP Adjusted Effective Tax Rate Income Tax Impact of Adjustments (4) Income Tax Adjustments (1) All amounts are approximate due to rounding. (2) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non- GAAP performance measure provides useful information to investors. January 31, January 31, January 31, January 31, Reconciliation of US GAAP Income Before Taxes to Non-GAAP Adjusted Income Before Taxes Three Months Ended Nine Months Ended Three Months Ended Nine Months Ended JOHN WILEY & SONS, INC. SUPPLEMENTARY INFORMATION (1) (2) RECONCILIATION OF US GAAP MEASURES to NON-GAAP MEASURES (in USD thousands, except per share information) (unaudited)

------

![](exhibit992-q326earningsp027.jpg)

Appendix – Net Income to Adjusted EBITDA 2026 2025 2026 2025 Net Income (loss) 29,679$(22,954)$86,270$16,068$ Interest expense 11,490 14,027 34,202 41,277 Provision for income taxes 14,717 41,627 33,843 74,545 Depreciation and amortization 35,592 36,474 107,967 110,445 Non-GAAP EBITDA 91,478 69,174 262,282 242,335 Restructuring and related charges 7,057 5,574 16,127 13,071 Net foreign exchange transaction losses 5,187 4,222 5,202 7,316 Net loss on sale of businesses, assets, and impairment charges related to assets held-for-sale 161 15,930 3,586 9,760 Other expense (income), net 1,524 (1,021) 3,614 (4,029) Held for Sale or Sold segment Adjusted EBITDA - - - 3,578 Legal settlement - - 108 - Non-GAAP Adjusted EBITDA 105,407$93,879$290,919$272,031$ Adjusted EBITDA Margin 25.7% 23.2% 23.7% 22.3% Notes: (1) All amounts are approximate due to rounding. (2) See Explanation of Usage of Non-GAAP Performance Measures included in this supplementary information for additional details on the reasons why management believes presentation of each non-GAAP performance measure provides useful information to investors. January 31, January 31, Three Months Ended Nine Months Ended JOHN WILEY & SONS, INC. SUPPLEMENTARY INFORMATION (1)(2) RECONCILIATION OF US GAAP NET INCOME (LOSS) TO NON-GAAP EBITDA AND ADJUSTED EBITDA (in USD thousands) (unaudited)

------